Loading stock data…
$6.09-0.09 (-1.46%)
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities.
Instil Bio, Inc. in the Healthcare sector is trading at $6.09 with a market capitalization of $44M. Wall Street consensus targets $7.00 (1 analysts), implying a +14.9% move over the next 12 months. The stock is currently near its 52-week low of $5.67, remaining 22.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.40M↑ | -$6.02M↑ | -$9.56M↑ | -$15.02M↓ | -$12.90M |
| Net Income | -$4.30M↓ | -$4.20M↑ | -$8.19M↑ | -$13.59M↑ | -$21.39M |
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Inst...